L-Citrulline: The Nitric Oxide Precursor Research Guide

What Is L-Citrulline?

L-Citrulline is a non-essential amino acid named after Citrullus lanatus — the watermelon — in which it was first isolated in 1914. Unlike most amino acids, it does not serve as a direct building block for proteins. Instead, it functions as an intermediate in the urea cycle and, more importantly for performance researchers, as a precursor to L-arginine in the kidney — making it the most efficient route to raising plasma arginine levels discovered to date.

The compound is synthesized endogenously from glutamine and carbamoyl phosphate, and is present in dietary sources (watermelon, cucumber, bitter melon). Exogenous supplementation, however, delivers plasma arginine elevations that oral L-arginine itself cannot match, owing to arginine's significant first-pass metabolism in the intestinal mucosa and liver. This pharmacokinetic advantage has made citrulline the dominant research target for nitric oxide (NO) augmentation strategies.

Molecular Profile

Mechanism of Action

Citrulline's effects are mediated almost entirely through its conversion to L-arginine in the proximal tubule of the kidney, bypassing hepatic first-pass metabolism. This renal conversion is catalyzed by argininosuccinate synthetase and argininosuccinate lyase — enzymes operating with high capacity in renal tissue.

The resulting plasma arginine then serves as the substrate for nitric oxide synthase (NOS) isoforms — principally endothelial NOS (eNOS) — which catalyzes the conversion of arginine to NO and L-citrulline. This cycle (citrulline → arginine → NO + citrulline) is referred to as the citrulline-NO cycle.

Nitric oxide itself is a short-lived gasotransmitter that activates soluble guanylate cyclase, elevating intracellular cGMP, which drives smooth muscle relaxation and vasodilation. Secondary downstream effects include:

• Reduced vascular resistance — improving cardiac output efficiency
• Enhanced oxygen and nutrient delivery to working muscle
• Ammonia clearance augmentation — citrulline's direct urea cycle role helps buffer ammonia accumulation during high-intensity exercise
• Reduced phosphocreatine depletion rate (observed in some muscle biopsy studies)

Citrulline malate may offer additive benefit via malate's role as a Krebs cycle intermediate (anaplerosis), though this contribution is debated and likely minor relative to the citrulline component.

What the Research Actually Shows

Exercise Performance

The most consistent human trial finding is an improvement in resistance training volume. A frequently cited 2010 randomized crossover trial by Pérez-Guisado and Jakeman (Journal of Strength and Conditioning Research) found that 8 g of citrulline malate taken 60 minutes before a lower-body resistance session increased repetitions performed across all sets by ~52% versus placebo, with a significant reduction in muscle soreness at 24 and 48 hours post-exercise. The study was small (41 men), but the effect size is among the largest seen in any acute ergogenic intervention trial.

Subsequent meta-analyses have partially replicated this. A 2019 meta-analysis by Trexler et al. (Journal of Sport and Health Science) pooled 12 studies and found statistically significant effects on resistance exercise performance (hedges' g = 0.26), with stronger effects when citrulline malate rather than citrulline alone was used — though the authors note this may reflect dosing differences.

Effects on aerobic performance are more mixed. Studies using cycling time-to-exhaustion or VO₂max protocols show modest or non-significant benefits at standard doses (6–8 g). Higher-intensity intermittent protocols (e.g., repeated sprint ability) show more consistent positive effects. A 2021 trial in trained cyclists found 6 g citrulline malate improved mean power during a 4×4-minute cycling protocol by approximately 3–4%, a difference within the margin of practical significance for competitive athletes.

Blood Flow and Cardiovascular Endpoints

Multiple double-blind, placebo-controlled trials confirm that citrulline supplementation (3–6 g/day over 4–8 weeks) measurably increases plasma nitrite/nitrate levels — a proxy for NO production — and reduces arterial stiffness as measured by pulse wave velocity (PWV).

A 2017 trial (Wong et al.) in postmenopausal women found that 5.6 g/day watermelon extract (matched to ~2.7 g citrulline) reduced mean arterial pressure by 9 mmHg versus placebo over 6 weeks — a clinically meaningful reduction. A 2012 study using 6 g/day citrulline in hypertensive adults found similar reductions in brachial-ankle PWV. These cardiovascular effects appear more pronounced in populations with baseline endothelial dysfunction (hypertension, aging, diabetes-adjacent metabolic profiles).

Erectile Function

Because penile erection is mediated primarily by NO-driven smooth muscle relaxation in the corpus cavernosum, citrulline has been studied in mild erectile dysfunction. A 2011 single-blind crossover trial (Cormio et al.) found that 1.5 g/day L-citrulline for 1 month doubled the proportion of men with mild ED reporting improved erection hardness scores (33% → 68%), with a statistically significant improvement in intercourse satisfaction. The effect is well below that of PDE5 inhibitors, but the safety profile is notably benign.

Muscle Protein Synthesis

Emerging research — primarily in animal models — suggests citrulline may have a direct anabolic signaling effect independent of its NO pathway activity, possibly through mTORC1 activation. A 2015 rodent study (Jourdan et al.) found that citrulline supplementation improved muscle mass maintenance in sarcopenic conditions beyond what protein supplementation alone achieved. A small human trial in elderly men found that 10 g/day citrulline improved lean mass gain during a resistance training program more than control — but this study had methodological limitations and awaits replication.

L-Citrulline vs Citrulline Malate vs L-Arginine

The clinical differences between free-form citrulline and citrulline malate are modest and likely explained by total citrulline dose. Choosing between them is largely a matter of formulation preference.

Research Limitations

The citrulline literature has several consistent weaknesses:

Small sample sizes. Many trials enroll fewer than 40 subjects, limiting statistical power and generalizability. Effect sizes from small trials are often inflated.

Heterogeneous dosing protocols. Studies use anywhere from 3–10 g, in single or divided doses, with varying timing before exercise. Dose-response relationships have not been cleanly characterized in large trials.

Training status confounds. Untrained and recreationally active subjects tend to show larger performance improvements than well-trained athletes. The 52% repetition increase study cited above used untrained-to-recreationally-active men.

Outcome measure variability. Studies measure diverse endpoints (reps to failure, time to exhaustion, blood pressure, flow-mediated dilation, plasma arginine) making cross-study comparison difficult.

Limited long-term data. Most trials are 4–8 weeks. Cardiovascular effects in longer interventions (months to years) have not been characterized with rigorous RCT design.

Malic acid contribution unclear. Whether citrulline malate's anaplerotic effect from malate meaningfully contributes to performance over and above citrulline alone remains unresolved.

Key Takeaways

1. L-Citrulline reliably raises plasma L-arginine levels more effectively than supplemental L-arginine, due to bypassing intestinal and hepatic first-pass metabolism via renal conversion.
2. Human trial evidence for resistance exercise volume (reps to failure) is the most consistent performance benefit, with multiple randomized controlled trials showing statistically significant improvements.
3. Acute cardiovascular effects — reduced arterial stiffness, lower blood pressure in hypertensive individuals — are supported by several well-designed trials, particularly in populations with baseline endothelial dysfunction.
4. Effects on aerobic performance (VO₂max, time-to-exhaustion) are more variable and likely dose- and intensity-dependent.
5. Research in erectile function shows meaningful benefit in mild ED, though effects are substantially smaller than pharmaceutical PDE5 inhibitors.
6. Emerging data on anabolic signaling (mTORC1 pathway) is mechanistically interesting but requires replication in well-powered human trials.
7. Citrulline malate (2:1) is the most common form used in performance studies; free-form L-citrulline appears equivalent when dosed to match citrulline content.
8. The citrulline literature is limited by small sample sizes and heterogeneous protocols — treating any individual study result as definitive is premature.

This article is for informational and research reference purposes only. L-Citrulline is an amino acid available as a dietary supplement and is generally regarded as safe. This content is not medical advice and should not be used to diagnose, treat, or prevent any condition. Consult a qualified healthcare provider before making changes to supplementation protocols.